Finance

Beta
Lists
CGEM:NASDAQ
Cullinan Therapeutics Inc
US$ १७.६९
+७.८०%
(+१.२८) 1D
US$ १७.६९
०.००% (०.००)
After hours
Closed: जुलाई १७, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CGEM...
Open
US$ १६.०६
High
US$ १७.८८
Low
US$ १६.००
Mkt. cap
१.०९ अरब
Avg. vol.
१२.०५ लाख
Volume
५.९५ लाख
52-wk high
US$ १९.४३
52-wk low
US$ ५.६८
EPS
-US$ ३.७२
Beta
-०.०२
Shares outstanding
६.१५ करोड
No. of employees
१०९
Open
US$ १६.०६
High
US$ १७.८८
Low
US$ १६.००
Mkt. cap
१.०९ अरब
Avg. vol.
१२.०५ लाख
Volume
५.९५ लाख
52-wk high
US$ १९.४३
52-wk low
US$ ५.६८
EPS
-US$ ३.७२
Beta
-०.०२
Shares outstanding
६.१५ करोड
No. of employees
१०९
News stories
From sources across the web
Stock Traders Daily
Stock Traders Daily
·
१ दिन पहिले
Why (CGEM) Price Action Is Critical for Tactical Trading
About Cullinan Therapeutics Inc
CEO-
Employees१०९
Founded२०१६
Headquarters-
Sector-
Analyst ratings
Based on 11 analysts giving stock ratings to CGEM in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for CGEM in the last 3 months.
Highest
Current US$ १७.६९
US$ ४६.०० (+१६०.०३%)
Average
US$ ३३.५६ (+८९.७१%)
Lowest
US$ २४.०० (+३५.६७%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$ ३०.००
+६९.६%
06/24/2026
Robert Driscoll
Wedbush
Buy
Maintained
US$ ३७.००
+१०९.२%
06/11/2026
Julian Harrison
BTIG
Buy
Reiterated
US$ ३८.००
+११४.८%
06/10/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
06/10/2026
Kaveri Pohlman
Clear Street
Buy
Maintained
US$ ४६.००
+१६०%
06/10/2026
Boris Peaker
JonesTrading
Buy
Maintained
US$ ३६.००
+१०३.५%
06/10/2026
Samantha Semenkow
Citi
Buy
Reiterated
US$ ३३.००
+८६.५%
06/10/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
US$ २८.००
+५८.३%
06/08/2026
Sean Laaman
Morgan Stanley
Buy
Maintained
US$ ३०.००
+६९.६%
06/07/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
06/08/2026
David Dai
UBS
Buy
Initiated
US$ २४.००
+३५.७%
06/08/2026
Soumit Roy
JonesTrading
Buy
Maintained
US$ ३६.००
+१०३.५%
04/06/2026
Bradley Canino
Guggenheim
Buy
Reiterated
US$ ३०.००
+६९.६%
03/10/2026
Last report
२०२६ मे ७
Fiscal period
Q1 2026
EPS / Est. (USD)
-US$ ०.७५ / -US$ ०.८४
+११.०६%beat
Revenue / Est. (USD)
- / ०.००
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
६.१० करोड
४.२० करोड
४.२९ करोड
४.२१ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
१.४८ करोड
१.३६ करोड
१.२३ करोड
१.१६ करोड
Operating expense
७.५८ करोड
५.५६ करोड
५.५३ करोड
५.३७ करोड
Total operating expenses
७.५८ करोड
५.५६ करोड
५.५३ करोड
५.३७ करोड
Operating income
-७.५८ करोड
-५.५६ करोड
-५.५३ करोड
-५.३७ करोड
Other non operating income
-१.८१ लाख
-१.०८ लाख
-६९.०० हजार
-६२.०० हजार
EBT including unusual items
-७.०१ करोड
-५.०६ करोड
-५.०७ करोड
-४.९७ करोड
EBT excluding unusual items
-७.०१ करोड
-५.०६ करोड
-५.०७ करोड
-४.९७ करोड
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-७.०१ करोड
-५.०६ करोड
-५.०७ करोड
-४.९७ करोड
Net profit margin
-
-
-
-
Earnings per share
-१.०७
-०.७७
-०.७७
-०.७५
Interest and investment income
५९.२४ लाख
५०.९३ लाख
४६.१५ लाख
४०.९८ लाख
Interest expense
-
-
-
-
Net interest expenses
५९.२४ लाख
५०.९३ लाख
४६.१५ लाख
४०.९८ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-७.५७ करोड
-५.५५ करोड
-५.५२ करोड
-५.३६ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more